A randomised trial of [(18)F]PSMA‐1007‐PET/CT versus NaF‐PET/CT for staging primary prostate cancer: A trial protocol

BACKGROUND: Prostate‐specific membrane antigen (PSMA)‐positron emission tomography/contrast‐enhanced computed tomography (PET/CT) is a sensitive imaging modality for prostate cancer (PCa). Due to lack of knowledge of the patient benefit, PSMA‐PET/CT is not yet recommended in the European guidelines...

Descripción completa

Detalles Bibliográficos
Autores principales: Buch‐Olsen, Karen Middelbo, Poulsen, Mads Hvid, Hansen, Steinbjørn, Vilstrup, Mie Holm, Holm, Jorun, Hess, Søren, Holdgaard, Paw Christian, Zieger, Karsten Egbert Arnold, Madsen, Søren Sørensen, Gerke, Oke, Pedersen, Kasper Tholstrup, Dam, Johan Hygum, Langkjær, Niels, Østergaard, Louise Dorner, Asmussen, Jon Thor, Braad, Poul Erik, Nørgaard, Birgitte, Eiber, Matthias, Hildebrandt, Malene Grubbe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Study Protocols
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447207/
https://www.ncbi.nlm.nih.gov/pubmed/37636207
http://dx.doi.org/10.1002/bco2.243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447207/
https://www.ncbi.nlm.nih.gov/pubmed/37636207
http://dx.doi.org/10.1002/bco2.243

Ejemplares similares